Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis.

ABSTRACT:

Background

There is no consensus on the most effective treatments of pulmonary arterial hypertension (PAH). Our objective was to compare effects of medications for PAH.

Methods

We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrials.gov from inception to December 2021. We performed a frequentist random-effects network meta-analysis on all included trials. We rated the certainty of the evidence using the Grades of Recommendation, Assessment, Development, and Evaluation approach.

Results

We included 53 randomised controlled trials with 10 670 patients. Combination therapy with endothelin receptor antagonist (ERA) plus phosphodiesterase-5 inhibitors (PDE5i) reduced clinical worsening (120.7 fewer events per 1000, 95% CI 136.8-93

SUBMITTER: Pitre T 

PROVIDER: S-EPMC9724821 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature